Blood Test for Early Pancreatic Cancer Detection in Newly Diagnosed Diabetes
Tests a blood test for early pancreatic cancer in adults with new diabetes.
Plain-language title generated from the registry record
Registry title: Surveillance of Pancreatic Health After Diabetes Diagnosis
Key facts
- Where
- Ashton-under-Lyne, Birmingham, Bournemouth, Brockham, Bromborough, Burton-on-Trent, Epsom, Kibworth Beauchamp, Kingswinford, Leek, Leicester, London, Maidstone, Manchester, Nottingham, Portsmouth, Rossendale, Ruislip, Sandbach, Southampton, Stratford-upon-Avon, Uttoxeter, Uxbridge, Walsall, Warlingham, and Weymouth, United KingdomSee the 31 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 84 years old?
Source: NCT06803771, who can take part
Where in United Kingdom
- Ashton Medical GroupAshton-under-Lyne, United KingdomNo longer taking part
- Yardley Wood Health CentreBirmingham, United KingdomTaking people
- Bournemouth Research HubBournemouth, United KingdomNo longer taking part
- Brockwood Medical PracticeBrockham, United KingdomTaking people
- Eastham Group PracticeBromborough, United KingdomTaking people
- Peel Croft SurgeryBurton-on-Trent, United KingdomTaking people
- Integrated Care Partnership/ The Old Cottage HospitalEpsom, United KingdomTaking people
- South Leicestershire Medical GroupKibworth Beauchamp, United KingdomTaking people
- Kingswinford Medical PracticeKingswinford, United KingdomTaking people
- Park Medical CentreLeek, United KingdomTaking people
- Forest Medical GroupLeicester, United KingdomTaking people
- South Westminster CentreLondon, United KingdomTaking people
- The Cuckoo Lane PracticeLondon, United KingdomTaking people
- Willesden Medical CentreLondon, United KingdomTaking people
- Maidstone and Tunbridge Wells NHS TrustMaidstone, United KingdomTaking people
- Bodey Medical CentreManchester, United KingdomNo longer taking part
- Bowland Medical PracticeManchester, United KingdomNo longer taking part
- The Maples Medical CentreManchester, United KingdomNo longer taking part
- King's Mill Hospital (Sherwood Forest) Research VanNottingham, United KingdomTaking people
- Portsmouth Research HubPortsmouth, United KingdomNo longer taking part
- Hazelvalley Family PracticeRossendale, United KingdomTaking people
- Pembroke Centre (Hillingdon)Ruislip, United KingdomTaking people
- Ashfields Primary Care CentreSandbach, United KingdomNo longer taking part
- Moorgreen HospitalSouthampton, United KingdomTaking people
- Southampton Research Hub (Shirley Research Hub)Southampton, United KingdomNo longer taking part
- Trinity Court SurgeryStratford-upon-Avon, United KingdomTaking people
- Balance Street Health CentreUttoxeter, United KingdomTaking people
- Civic CentreUxbridge, United KingdomTaking people
- Quinton PracticeWalsall, United KingdomTaking people
- Warlingham Green Medical PracticeWarlingham, United KingdomTaking people
- Weymouth Research HubWeymouth, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Southampton NHS Foundation Trust
- Trial code
- NCT06803771
- Record updated
- 28 September 2026
- Original description
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.Read full original descriptionShow less
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
* attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.
Inclusion: 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth); Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range; Willing to provide up to 30 mL of blood for each study visit; Willing and eligible to undergo MRI or CT scan; Understands the study process and is willing to take part in the study and sign the informed consent form.
Exclusion: Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months; Solid organ transplant recipient; A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis; Under investigation for or confirmed pancreatic cancer; Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years; Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c; Under investigation/surveillance for pancreatic cyst; BMI > 40 at the time of consent; Blood transfusion within 1 month; Currently pregnant; Needing dialysis.